培美曲塞胸、腹腔灌注治疗恶性肿瘤的疗效及副反应观察  

Pemetrexed chest,efficacy and side effects observation of intraperitoneal infusion in treating malignant tumor

作　　者：聂春兰[1] 黄大福[1] 徐晖 侯莹[1] 张雷 李贺群 严波 NIE Chun-lan;HUANG Da-fu;XU Hui;HOU Ying;ZHANG Lei;LI He-qun;YAN Bo＊(Lishui people＇s Hospital,Jiangsu Nanjing 211200,China)

机构地区：[1]溧水人民医院,江苏南京211200

出　　处：《临床医药文献电子杂志》2018年第34期8-10,共3页Electronic Journal of Clinical Medical Literature

摘　　要：目的探讨培美曲塞胸、腹腔灌注治疗恶性肿瘤的疗效和副反应。方法以2015年10月~2017年10月我院收治的53例恶性肿瘤伴胸腹腔积液患者为研究对象,全部患者均行胸、腹腔灌注治疗,随机将入选病例分为两组。实验组27例,患者用药培美曲塞;对照组26例,患者用药顺铂或紫杉醇。疗程结束后,对比观察两组胸腹水控制率、功能状态、用药毒副反应及患者中位生存时间。结果实验组胸腹水控制率85.19%,KPS功能状态改善率77.78%,副反应发生率25.93%,中位生存时间11.3个月,各项指标均优于对照组,差异有统计学意义(P<0.05)。结论培美曲塞胸腹腔灌注治疗恶性肿瘤对胸腹腔积液控制效果良好,有助于患者功能状态改善,而且副反应少且轻,疗效优于常规抗肿瘤药物灌注,值得临床推广使用。Objective To study the pemetrexed malignant tumors of thoracic and abdominal cavity perfusion in the treatment efficacy and side effects.Methods The October 2015-October 2017 retrospectively 53 cases of malignant tumor complicated with hydrothorax of patients for the study,all patients were treated with chest,abdominal cavity perfusion,selected cases were randomly divided into two groups.27 patients in the experimental group,patients with pemetrexed,26 cases of the control group, patients with cisplatin or paclitaxel.After the course,compared two groups of pleural and peritoneal effusion control rate,functional status,drug toxicity and median survival time in patients with.Results Pleural and peritoneal effusion control rate of 85.19%,KPS function in the experimental group improved rate of 77.78%,the incidence of 25.93%,11.3 months median survival time,the indicators are better than the control group, a statistically significant difference（P〈0.05）.Conclusion Pemetrexed pleural infusion treatment of malignant hydrothorax control works well,helps patients improve, and fewer side effects and light,compared to conventional antitumor drug,worth of clinical use.

关 键 词：恶性肿瘤 培美曲塞 胸腹腔灌注 疗效 副反应 

分 类 号：R73[医药卫生—肿瘤]